MARS Bioimaging, a Christchurch, New Zealand‑based medical device company, raised $15 million in Series A funding.

The round was led by Pacific Channel and consisted of two tranches: $7.6 million in an initial close, followed by $7.4 million in new capital in 2026, for a total of $15 million.

The company intends to use the funds to accelerate the commercial adoption of its spectral photon‑counting CT scanners, which deliver 3‑D colour X‑ray imaging with advanced material differentiation, across key markets including the United States, New Zealand and select emerging markets such as India.

Led by CEO Dr Ojas Mahapatra, MARS Bioimaging is a medical imaging company that specializes in spectral molecular imaging. It has developed a commercially available portable spectral photon‑counting CT scanner, designed for a range of clinical and research applications, including orthopaedics and the development of new contrast agents. Its imaging systems leverage Medipix technology developed at CERN by the Medipix3 Collaboration, which includes the University of Canterbury.

The compact system visualises soft tissue, bone, blood vessels and metallic implants, without the need to inject X‑ray contrast agents into the patient.

FinSMEs

15/01/2026